ArticleInflammation2023
Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Psoriasis Through TNF-α/NF-κB/MMP13 Pathway.
Article in Inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Umbilical Cord Mesenchymal Stem Cells as a Meritorious Option to Treat Psoriasis.Current stem cell research & therapy · 2026Review
- The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.Frontiers in immunology · 2026Review
- Therapeutic Potential of Mesenchymal Stem Cells in Psoriasis.Cell biochemistry and biophysics · 2025Review
- The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects.International journal of molecular sciences · 2025Review
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges.Stem cell research & therapy · 2025Review
- Review
- Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.Clinical reviews in allergy & immunology · 2025Review
- Harnessing the Anti-Inflammatory Effects of Perinatal Tissue Derived Therapies for the Treatment of Inflammatory Skin Diseases: A Comprehensive Review.Stem cell reviews and reports · 2025Review
- The Differentiation and Regeneration Potential of ABCB5Journal of clinical medicine · 2025Review
- Recent advances on Hippo-YAP pathway in skin diseases.Frontiers in immunology · 2025Review
- Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series.Frontiers in immunology · 2025Article
- Repeat-dose toxicity of human umbilical cord mesenchymal stem cells via subcutaneous injection in NOG mice.Frontiers in cell and developmental biology · 2025Article
- Psoriasis: The Versatility of Mesenchymal Stem Cell and Exosome Therapies.Biomolecules · 2024Review
- Research progress and prospects of benefit-risk assessment methods for umbilical cord mesenchymal stem cell transplantation in the clinical treatment of spinal cord injury.Stem cell research & therapy · 2024Review
- Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials.Aging and disease · 2024Review
- DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.Translational cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Psoriasis is a chronic, immune-mediated disease that affects 2-3% of the global population. Recently, mesenchymal stem cells (MSCs) have been used to alleviate psoriasis. However, the therapeutic mechanisms of MSCs remain unclear. Matrix metalloproteinase-13 (MMP13), a member of the MMPs family, is the key enzyme in the cleavage of type II collagen and plays a pivotal role in extracellular matrix (ECM) remodeling. Here, it was found that Mmp13 was upregulated in the skin lesions of an imiquimod-induced mouse model, which was downregulated after intravenous infusion of human umbilical cord MSCs (hUC-MSCs). Knockdown of MMP13 inhibited the proliferation of keratinocytes and arrested the cell cycle in G1 stage. In addition, hUC-MSCs were co-cultured with THP-1 or PMA-stimulated THP-1 directly in vitro to simulate the fate of systematically infused hUC-MSCs. The level of TNF-α was decreased in the supernatant of co-cultured hUC-MSCs and THP-1 or PMA-stimulated THP-1. Moreover, it was identified that TNF-α upregulated MMP13 through the NF-κB pathway in keratinocytes. In conclusion, we propose that systematically infused hUC-MSCs exert a therapeutic effect on psoriasis through the TNF-α/NF-κB/MMP13 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.